Crestchem Ltd

As of November 19, 2025, Crestchem is fairly valued with a PE ratio of 17.38 and has underperformed the Sensex with a year-to-date return of -58.22%, making it less attractive compared to peers like Godrej Industries and Solar Industries.

As of 19-Nov, Crestchem Ltd's stock price is at 117.00, down 3.7% and significantly underperforming its sector and the Sensex. The stock is in a bearish trend, trading below all major moving averages, with a year-to-date decline of 58.22%, despite increased investor participation.

As of 18-Nov, Crestchem Ltd's stock price is Rs 116.50, up 3.6% today after three days of decline, but it has a year-to-date drop of 58.40%. Despite today's rebound and increased trading activity, the stock remains underperforming compared to the market.

As of November 17, 2025, Crestchem is considered very attractive and undervalued with a PE ratio of 17.38, an EV to EBITDA ratio of 15.34, and a ROCE of 30.63%, significantly lower than its expensive peers, indicating strong growth potential despite a year-to-date stock decline of 58.22%.

As of 17-Nov, Crestchem Ltd's stock price is Rs. 117.00, down 2.17%, and has reached a 52-week low of Rs. 110. The stock is underperforming significantly, trading below all key moving averages and experiencing a 58.22% decline year-to-date, contrasting sharply with the Sensex's 8.72% gain.

As of November 14, 2025, Crestchem's valuation has shifted to attractive with a PE ratio of 17.82, significantly lower than peers like Solar Industries and Gujarat Fluoroch, despite a year-to-date return of -57.15%, indicating it remains well-positioned in the specialty chemicals industry.

As of November 14, 2025, Crestchem is considered fairly valued with a PE ratio of 17.82, an EV to EBITDA of 15.74, and a ROE of 25.03%, showing strong historical growth potential despite recent underperformance compared to the Sensex.

As of November 14, 2025, Crestchem is considered an attractive investment opportunity in the specialty chemicals sector, assessed as undervalued with a PE ratio of 17.82, significantly lower than its peers, despite a year-to-date stock decline of 57.15% compared to the Sensex's gain of 8.22%.

Crestchem has shown significant growth in net sales and profitability, with net sales increasing from 7.64 Cr in Mar'21 to 25.08 Cr in Mar'25, and profit after tax rising from 0.57 Cr to 2.73 Cr during the same period. The company's financial performance reflects strong operational efficiency and enhanced shareholder value.

Crestchem's latest Q2 FY26 results show a sequential profit increase of 54.29% and revenue growth of 42.94%, but year-on-year declines of 46.00% in profit and 7.82% in revenue indicate ongoing challenges. While the balance sheet is strong, margin pressures and fluctuating return on equity suggest significant operational difficulties that need to be addressed.

Crestchem has experienced significant growth in net sales and profitability, with net sales rising from 7.64 Cr in Mar'21 to 25.08 Cr in Mar'25, and profit after tax increasing from 0.44 Cr to 2.73 Cr in the same period. The company's earnings per share also improved from 1.47 to 9.1, reflecting a strong upward trend in financial performance.

Crestchem is scheduled to declare its results on 12 November 2025.

As of 28-Oct, Crestchem Ltd's stock price is at 122.50, reflecting a decline of 0.12% and a total drop of 5.48% over the last two days. The stock is underperforming significantly compared to the market, with a year-to-date decline of 56.26%, despite increased investor participation.

Crestchem has demonstrated strong financial growth from March 2019 to March 2025, with net sales rising from 0.10 Cr to 25.08 Cr and profit after tax increasing from a loss of 0.17 Cr to a profit of 2.73 Cr, alongside significant improvements in total assets and shareholder value.

As of 27-Oct, Crestchem Ltd's stock price is at 122.00, down 5.86% and significantly underperforming its sector and the broader market. The stock has seen a year-to-date decline of 56.44% and a notable drop in trading volume, indicating ongoing challenges for the company.